Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Buy" from Brokerages

Key Points

• Theravance Biopharma has received a consensus rating of "Buy" from five research firms, with an average 12-month target price of $23.00.
• Significant upgrades have been noted, including Zacks raising the stock from "hold" to "strong-buy" and BTIG increasing its price target from $24.00 to $25.00.
• Insider Rhonda Farnum sold 10,000 shares of the company at $11.39 each, reducing her ownership by 2.97% while institutional investors collectively hold 99.10% of the stock.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has received a consensus rating of "Buy" from the five research firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $23.00.

Several analysts have issued reports on the stock. Zacks Research raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. BTIG Research upped their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research report on Tuesday, June 17th. Wall Street Zen raised shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Finally, B. Riley assumed coverage on shares of Theravance Biopharma in a research report on Friday. They set a "buy" rating and a $28.00 price target on the stock.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP grew its stake in Theravance Biopharma by 11.9% during the first quarter. GSA Capital Partners LLP now owns 182,350 shares of the biopharmaceutical company's stock worth $1,628,000 after buying an additional 19,363 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Theravance Biopharma by 3.8% in the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after purchasing an additional 2,293 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Theravance Biopharma by 1.5% in the 1st quarter. Bank of New York Mellon Corp now owns 117,499 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 1,720 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $119,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Theravance Biopharma by 27.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company's stock valued at $1,412,000 after purchasing an additional 32,534 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Stock Up 0.4%

Shares of TBPH stock opened at $13.70 on Friday. The company's fifty day simple moving average is $12.33 and its 200-day simple moving average is $10.56. The firm has a market cap of $689.93 million, a PE ratio of 57.08 and a beta of 0.05. Theravance Biopharma has a 12 month low of $7.88 and a 12 month high of $14.55.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.